BCAB trades 14309.2% below Wall Street's consensus target of $250.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BCAB achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, BioAtla, Inc. (BCAB) has a Wall Street consensus price target of $250.00, based on estimates from 9 covering analysts. With the stock currently trading at $1.74, this represents a potential upside of +14309.2%. The company has a market capitalization of $3M.
Analyst price targets range from a low of $250.00 to a high of $250.00, representing a 0% spread in expectations. The median target of $250.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BCAB trades at a trailing P/E of -0.0x. Analysts expect EPS to grow -143.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $7.1B | $34.54 | $40.00 | +15.8% | Buy | — | 23 |
 RCUSArcus Biosciences, Inc. | $3.3B | $26.39 | $40.00 | +51.6% | Buy | — | 18 |
 AGENAgenus Inc. | $350M | $8.40 | $25.00 | +197.6% | Buy | 10.8x | 11 |
 MGNXMacroGenics, Inc. | $242M | $3.80 | $6.00 | +57.9% | Buy | — | 22 |
 FATEFate Therapeutics, Inc. | $283M | $2.43 | $5.63 | +131.7% | Buy | — | 31 |
 MIRMMirum Pharmaceuticals, Inc. | $5.4B | $89.32 | $140.20 | +57.0% | Buy | — | 18 |
 ARVNArvinas, Inc. | $505M | $7.83 | $14.17 | +81.0% | Buy | — | 26 |
 NKTRNektar Therapeutics | $1.9B | $57.66 | $152.50 | +164.5% | Buy | — | 33 |
 AGIOAgios Pharmaceuticals, Inc. | $2.0B | $34.19 | $42.67 | +24.8% | Buy | — | 29 |
 REGNRegeneron Pharmaceuticals, Inc. | $82.6B | $801.82 | $827.71 | +3.2% | Buy | 14.7x | 49 |
Quick answers to the most common questions about buying BCAB stock.
The consensus Wall Street price target for BCAB is $250, representing 14309.2% upside from the current price of $1.735. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BCAB has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $250 implies 14309.2% upside from current levels.
BCAB's current price is $1.735 with a consensus target of $250 (14309.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $250 for BCAB, while the most conservative target is $250. The consensus of $250 represents the median expectation. These targets typically reflect 12-month expectations.
BCAB is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BCAB stock forecast based on 9 Wall Street analysts shows a consensus price target of $250, with estimates ranging from $250 (bear case) to $250 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on BCAB, with a "Buy" consensus rating and $250 price target (14309.2% upside). 6 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BCAB analyst price targets range from $250 to $250, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $250 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.